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ABSTRACT
Objectives: To compare the timelines and
recommendations of the Scottish Medicines
Consortium (SMC) and National Institute of Health and
Clinical Excellence (NICE), in particular since the single
technology assessment (STA) process was introduced
in 2005.
Design: Comparative study of drug appraisals
published by NICE and SMC.
Setting: NICE and SMC.
Participants: All drugs appraised by SMC and NICE,
from establishment of each organisation until August
2010, were included. Data were gathered from
published reports on the NICE website, SMC annual
reports and European Medicines Agency website.
Primary and secondary outcome
measures: Primary outcome was time from marketing
authorisation until publication of ﬁrst guidance. The
ﬁnal outcome for each drug was documented. Drug
appraisals by NICE (before and after the introduction of
the STA process) and SMC were compared.
Results: NICE and SMC appraised 140 drugs, 415
were appraised by SMC alone and 102 by NICE alone.
NICE recommended, with or without restriction, 90%
of drugs and SMC 80%. SMC published guidance
more quickly than NICE (median 7.4 compared with
21.4 months). Overall, the STA process reduced the
average time to publication compared with multiple
technology assessments (median 16.1 compared with
22.8 months). However, for cancer medications, the
STA process took longer than multiple technology
assessment (25.2 compared with 20.0 months).
Conclusions: Proportions of drugs recommended for
NHS use by SMC and NICE are similar. SMC publishes
guidance more quickly than NICE. The STA process
has improved the time to publication but not for cancer
drugs. The lengthier time for NICE guidance is partly
due to measures to provide transparency and the
widespread consultation during the NICE process.
INTRODUCTION
The National Institute of Health and Clinical
Excellence (NICE) provides guidance on the
use of new drugs in England and Wales.
There has been controversy over its deci-
sions, and the timeliness of drug appraisals,
particularly those concerning new cancer
drugs.
1e4 NICE does not appraise all new
drugs, but only those referred to it by the
Department of Health (DH), after scoping
and consultation.
In Scotland, the Scottish Medicines
Consortium (SMC) appraises all newly
licensed medications (including new indica-
tions for medicines with an existing license).
The simultaneous functioning of both orga-
nisations has been described as ‘comple-
mentary’,
5 but debate arises when differences
occur because of the implications for the
NHS of a drug being provided in England
but not in Scotland.
Flow charts outlining the processes are
given in ﬁgures 1 and 2 (e-version only).
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ARTICLE SUMMARY
Article focus
- Has the STA process resulted in speedier
guidance for NICE?
- What are the differences in recommendation and
timelines between SMC and NICE?
Key messages
- The STA system has resulted in speedier
guidance for some drugs but not for cancer
drugs.
- SMC publishes speedier guidance than NICE.
- SMC and NICE recommend a similar proportion
of drugs.
Strength and limitations of this study
- Although some differences by SMC and NICE are
shown, it is not possible in this study to say
which is correct.
- Accuracy of outcome data taken from NICE
website and SMC annual reports is unclear.
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Open Access ResearchEvolution of the NICE appraisal system
Before 2005, the main source of evidence for the NICE
technology appraisal committees was a technology
assessment report (TAR)da systematic review of clinical
and cost-effectiveness, usually with economic modelling,
produced by an independent assessment group. NICE
also received industry submissions including economic
modelling by the manufacturer, and these were reviewed
by the assessment group. The manufacturer was given an
opportunity to comment on the TAR. The process was
regarded as too time consuming and as leading to delays
in availability of new medications for patients, especially
controversial with new anticancer medications.
6 Primary
Care Trusts would often not fund new medications until
guidance was produced.
In 2005, NICE introduced the ‘single technology assess-
ment’ (STA) system wherein the main source of evidence
for the appraisal is a submission, including economic
evaluation and review of the clinical effectiveness, by the
manufacturer, which is critiqued by one of the assess-
ment groups. There is no independent systematic review
or modelling. Currently, most new drugs are appraised
under the new STA system, and the TAR-based system
(also called multiple technology assessment (MTA)) is
used for larger and more complex appraisals, such as for
several drugs for the same condition, or, less often, one
drug for several conditions.
The STA system is similar to that which has been used
by SMC, where the main evidence is an industry
submission, critiqued by SMC staff with a short summary
of the critique being published with the guidance.
During the STA process, an independent academic
group critiques the industry submission, and the
‘evidence review group’ report is published in full
(except for commercial or academic in conﬁdence data)
on the NICE website, making the STA process more
transparent. In cases where SMC issue guidance on
a medicine and it is then appraised by NICE using the
MTA system, NHS Healthcare Improvement Scotland
reviews the NICE MTA guidance and generally accepts it
for use in Scotland, implicitly reﬂecting an assumption
that the wider scope of an MTA and the extra work
Figure 1 Scottish Medicines
Consortium (SMC) pathway.
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NICE, the STA process and SMCinvolved in the review allowed more evidence to be
considered and analysis undertaken; the same argu-
ments do not apply to NICE STA guidances and hence
they are not used in Scotland.
There are two aims in this study. First, since it has been
6 years since the introduction of the STA process by
NICE, it is timely to assess whether the change has been
associated with speedier guidance. Second, we compare
recommendations and timelines between NICE and
SMC.
METHODS
For all drugs appraised by both NICE and SMC, we
calculated the time from marketing authorisation
(obtained from the European Medicines Agency
website) until publication of guidance. NICE data were
taken from the technology appraisal guidance docu-
ments on their website. SMC data were extracted from
annual reports and detailed appraisal documents. Drugs
were deﬁned as ‘recommended (NICE) or accepted
(SMC)’, ‘restricted’ or ‘not recommended’, according to
classiﬁcation in the tables of appraisals published on the
NICE website or SMC annual reports. The term
‘restricted’ can have various meanings, such as place in
treatment pathway, patient group, or clinical setting. All
medications appraised from the establishment of each
organisation until August 2010 were included. When
guidance differed, we examined possible reasons, noting
if the difference was only about restrictions on use,
rather than approval versus non-approval.
RESULTS
NICE and SMC appraised 140 drugs, 415 drugs were
appraised only by SMC and a further 102 only by NICE
(which started 3 years before SMC). The higher number
appraised by SMC reﬂects SMC’s practice of appraising
all newly licensed drugs, whereas only selected drugs are
appraised by NICE.
Figure 2 National Institute of
Health and Clinical Excellence
(NICE) pathway. ACD, Appraisal
Committee Document; ERG,
Evidence Review Group; FAD,
Final Appraisal Determination.
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NICE, the STA process and SMCTimeliness: NICE before and after the introduction of STAs
The main reason that NICE introduced the STA system
was to allow patients, especially those suffering from
cancer, quicker access to medications. The time from
marketing authorisation to appraisal publication is
presented in table 1. After 2005, the STA process
reduced the time to publication of guidance. There is
marked variability in NICE data throughout the years.
For example, in 2009, the median time to publication for
STAs was 8 months (range 4e38), but in 2010, the
median time was 29 months (range 4e30). However,
although the STA system has reduced the time from
marketing authorisation to issue of guidance (median
16.1, range 4e41 months) months compared to 22.8
(range 2e77) months for MTAs, it has failed to reduce
the time for anticancer medications. For STAs of cancer
products, the appraisal process took an average of 25.2
(range 4e41) months compared with 20.0 (range
2e46) months for cancer-related MTAs.
This increased length of appraisal is also reﬂected
within SMC; anticancer drug appraisals take longer
(median 8.0 months, range 1e29) months compared
with 7.3 months (range 1e44) for all SMC drugs.
There was no signiﬁcant difference between multi-
drug and single-drug MTAs (median 22.8 months, range
2e77 and 21.5 months, range 3e58, respectively).
Timelines: NICE versus SMC
Comparing all appraised drugs, from marketing
authorisation to publication, NICE guidance takes
considerably longer, as shown in table 2, at median
21.4 months, compared to 7.4 months for SMC. For
drugs appraised by both organisations, NICE guidance
took a median 15.7 months longer than SMC guidance.
In the SMC process, the Detailed Advice Document is
distributed for 1 month to health boards for information
and to manufacturers to check factual accuracy.
Differences in recommendations between NICE and SMC
NICE and SMC appraised 140 drugs, 415 drugs were
appraised only by SMC and a further 102 only by NICE
(which started 3 years before SMC). The higher number
appraised by SMC reﬂects SMC’s practice of appraising
all newly licensed drugs, whereas only selected drugs are
appraised by NICE. Of the 140 comparable appraisals,
the same outcome was reached in 100 (71.4%), the same
outcome but with a difference in restriction in 27
(19.3%) and a different outcome in 13 (9.3%). Details of
the differences, and possible reasons, are shown in table 3.
It was found that 90.1% of all medications appraised by
NICE were recommended, with or without restriction,
71.5% were deﬁned as recommended and 18.6% as
restricted, whereas 80% of medications were recom-
mended by SMC, with or without restriction (39.3%
deﬁned as accepted and 41.1% deﬁned as restricted), as
shown in table 4. (Note that these tables reﬂect how
NICE and SMC have categorised their decisions and they
may not be comparable as discussed below.)
However, the differences are often less than these
ﬁgures suggest because NICE sometimes approves
a drug for very restricted use. For example, NICE
approved pimecrolimus ‘for very restricted use for the
second-line treatment of moderate atopic eczema on the
face and neck in children aged 2e16 that has not been
controlled by topical steroids and only where adverse
effects such as irreversible skin atrophy were likely’d
four restrictions by age, site, previous treatment and risk
of adverse effects. SMC rejected it entirely. Although it
was recommended by NICE but not by SMC, there may
be very little difference in the amount of drug used.
The approval rate was lower for cancer drugs
compared to non-cancer ones. NICE appraised 80
cancer drugs, 16 (20%) of which were not recom-
mended. SMC appraised 98 cancer drugs and 29
(29.6%) were not recommended.
Table 1 SMC and NICE times to guidance by year
SMC NICE
Year Number
Median
(months)
Range
(months) Total
Median
(months)
Range
(months) MTAs
Median
(months)
Range
(months) STAs
Median
(months)
Range
(months)
2000 NA 4 14 4e19 4 14 4e19 NA NA NA
2001 NA 4 13 3e17 4 13 3e17 NA NA NA
2002 23 5 1e23 11 18 9e29 11 18 9e29 NA NA NA
2003 57 7 1e30 10 34 7e46 10 34 7e46 NA NA NA
2004 59 8 1e32 13 22 2e35 13 22 2e35 NA NA NA
2005 71 8 1e29 2 11 3e19 2 11 3e19 NA NA NA
2006 94 6 1e44 21 21 6e77 19 21 6e77 2 19 17e20
2007 84 7 1e24 19 26 9e58 9 35 24e58 10 24.5 9e41
2008 72 7 1e30 21 26 2e60 11 36 2e60 10 12.5 5e37
2009 66 7 1e24 21 20 4e46 8 28.5 20e46 13 8 4e38
2010 30 10 1e30 4 29.5 4e35 1 35 NA 3 29 4e30
MTA, multiple technology assessments; NA, not applicable; NICE, National Institute of Health and Clinical Excellence; SMC, Scottish Medicines
Consortium; STA, single technology assessment.
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NICE, the STA process and SMCDISCUSSION
The NICE STA process was introduced in 2005, with the
intention of producing speedier guidance, especially for
cancer medication. Our analysis shows that the intro-
duction of the NICE STA process has resulted in speedier
guidance but not for cancer drugs. There are some
differences in recommendations between NICE and
SMC, with SMC rejecting a great proportion of the drugs
appraised by both organisationsd20% versus 10%.
Reason for difference in recommendations
The reasons for different recommendations might be
expected to include:
< NICE sometimes allowed cost per QALY exceeding
the upper bound of its cost-effectiveness threshold
(£30000 per QALY); especially after the ‘end-of-life’
additional guidance was adopted. However, in several
instances, NICE did not report their estimated cost
per QALY. SMC can also accept a cost per QALY over
£30000 but seems not to do so to the same extent as
NICE.
< Different timings, sometimes by years, during which
time ‘patient access schemes’, with part-funding
by manufacturers, were introduced into NICE
calculations.
< The modelling from the manufacturer was sometimes
different. For example, SMC considered telbivudine
to be cost-effective compared to entecavir for the
treatment of chronic hepatitis B, but the manufac-
turer’s submission to NICE did not include entecavir.
< Evolution of evidence base.
< Longer appraisals provide more opportunities to
explore subgroups. Therefore, differences may arise
between decisions if one organisation has time to
evaluate numerous subgroups within a population.
< The difference in timelines means that if a drug is
rejected by SMC, the manufacturer may be able to
revise the modelling before the drug goes to NICE.
Reasons for lengthier NICE appraisals
The causes for the lengthier process at NICE include
consultation
7 and transparency. NICE produces a consid-
erably more detailed report and explanation of how the
decision was reached. Publically available material
includes drafts and ﬁnal scopes, responses by consultees
and commentators and a detailed ﬁnal appraisal deter-
mination. Our impression (two of us have been associ-
ated with NICE appraisal for many years) is that the
length of the Appraisal Consultation Decisions and Final
Appraisal Determination has increased over the years.
More recently, we have noted that drugs may be consid-
ered more often by the appraisal committee than the
expected two timesdthere are examples of drugs going
to three and four meetings. In the STA process, NICE
may issue a ‘minded no’ and give the manufacturer more
than the usual interval in which to respond with further
submissions. This in turn sometimes leads to the
Evidence Review Group asking for more time to consider
the new submissions. Hence, drugs may received very
detailed consideration, but at a time cost.
Marked variability throughout the years (table 1)i s
most likely caused by small numbers, especially in 2010,
where only three STAs are included. Excluding 2010,
there has been a general trend for shortening STA times
and lengthier MTA times. This is unsurprising, since
more complex appraisals would be assessed in an MTA.
The longest appraisals (77 months for etanercept in
psoriatic arthritis and 60 months for inﬂiximab for
ankylosing spondylitis) are explained by the fact that
NICE can appraise older drugs if referred by the DH.
Both of these were appraised in an MTA with other
drugs.
SMC publishes considerably fewer details. NICE
appraisal committees deal with two to three STAs per
day, allowing for both public and private sessions. SMC is
able to deal with six to seven new drugs per day. NICE
allows a 2-month period between appraisal committee
meetings, 1 month for consultation and then a period
for the evidence review group and the NICE secretariat
to reﬂect on these comments and produce a commen-
tary for the second meeting of the appraisal committee.
Comments on the draft guidance (the Appraisal
Consultation Decision) come from manufacturers (of
drug and comparators), clinical groups such as Royal
Colleges, NHS staff, patients and the general public
through the consultation facility on the NICE website.
Figures 1 and 2 (e-version) demonstrate the pathway of
appraisal for SMC and NICE.
There is a trade-off between consultation and timeli-
ness. The emphasis by NICE on wide consultation,
compared to the less extensive approach by SMC, may
simply be a function of size of territory. SMC and its New
Drugs Committee have representatives from most health
boards. (Note that in Scotland, trusts have been abol-
ished and NHS boards are unitary authorities providing
both primary and secondary care, so representatives
include managers and clinicians). This in effect allows
consultation as part of the process, though mainly with
NHS staff rather than patients and public. Patient
interest groups have the opportunity to submit written
comments to the SMC in support of a new medicine. In
Table 2 Median time from marketing authorisation to
guidance publication
All drugs Cancer drugs
Marketing authorisation
to SMC, months (range)
7.35 (1e44) 8.00 (1e29)
Marketing authorisation
to NICE, months (range)
21.40 (2e77) 23.62 (2e46)
Marketing authorisation
to STA, months (range)
16.05 (4e41) 25.23 (4e41)
Marketing authorisation
to MTA, months (range)
22.81 (2e77) 20.02 (2e46)
MTA, multiple technology assessments; NICE, National Institute of
Health and Clinical Excellence; SMC, Scottish Medicines
Consortium; STA, single technology assessment.
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NICE, the STA process and SMCTable 3 Differences between NICE and SMC appraisals
NICE product Condition Decisions Reason PAS
Inﬂiximab Crohn’s disease
(active severe in
adults)
Recommended
by NICE, not
by SMC
SMC (April 2007): manufacturer
did not present a sufﬁciently robust
economic case
NICE (2010): recommended in patients
who have not responded to conventional
treatment or have contraindication to
conventional treatment, until treatment
failure or 12 months. The assessment
group estimated the ICER to be £68000
No
Inﬂiximab Crohn’s disease
(ﬁstulising)
Recommended
by NICE, not
by SMC
SMC (April 2007): manufacturer’s
justiﬁcation of the treatment cost in relation
to its health beneﬁts was not sufﬁcient
NICE (2010): recommended in patients
who have not responded to conventional
treatment or have contraindication to
conventional treatment, until treatment
failure or 12 months. NICE assumed the
ICER to be £30000, so a borderline case
No
Inﬂiximab Acute, severely
active ulcerative
colitis
Recommended
by NICE, but not
by SMC
SMC: manufacturer did not present a
sufﬁciently robust economic case
NICE: recommended as a possible treatment
for people with acute, severely active
ulcerative colitis only if ciclosporin could
not be used. Otherwise should be used only
in trials
No
Inﬂiximab Severe ankylosing
spondylitis (adults)
Restricted by
SMC, not
recommended
by NICE
SMC: in 2004, SMC said that the economics
case had not been demonstrated. In 2005, it
was approved for very restricted use, as only
cost-effective ‘when rigorous stopping rules
were applied’. SMC later changed advice in
line with the NICE MTA
NICE (2008): in an MTA, inﬂiximab was not
cost-effective, especially compared with
etanercept and adalimumab. SMC had
considered inﬂiximab in isolation
No
Pimecrolimus Atopic dermatitis
(eczema)
Recommended
by NICE, not
by SMC
SMC: no evidence that it has clinical
advantage in terms of efﬁcacy or safety
when compared with the alternative
treatments and the economic case for using
this preparation is unproven
NICE: recommended for very restricted use
for the second-line treatment of moderate
atopic eczema on the face and neck in
children aged 2e16 years that has not been
controlled by topical corticosteroids, and only
where serious adverse effects such as
irreversible skin atrophy likely
No
Docetaxel
(in combination
with steroid)
Prostate cancer
(hormone-
refractory)
Recommended
by NICE, not
by SMC
SMC: the cost-effectiveness has not been
demonstrated
NICE: as a treatment option only if Karnofsky
performance status score is 60% or more.
N.B NICE allowed an ICER of £33000 as
being ‘acceptable cost-effective’
N.B SMC have changed their advice in
accordance with NICE MTA
No
Continued
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NICE, the STA process and SMCTable 3 Continued
NICE product Condition Decisions Reason PAS
Cinacalcet Hyperparathyroidism
(refractory)
Use very restricted
use by NICE, not
recommended
by SMC
SMC: the economic case was not
demonstrated
NICE: recommended for use in ‘extreme
situations’: people on dialysis who have
very high levels of parathyroid hormone in
their blood that cannot be lowered by other
treatments and cannot have a
parathyroidectomy because of the risks
involved. It is not clear from the guidance
what the ICER was estimated to be, but
in most situations, it was well above £30000
No
Telbivudine Chronic hepatitis B Recommended
by SMC, not
by NICE
SMC: approved on the grounds that it was
cost-effective compared to entecavir and
lamivudine
NICE: cost-effectiveness not proven. The
manufacturer’s submission did not include
any comparison with entecavir. NICE
commented that the complexity and lack
of transparency in the manufacturer’s model
undermined the credibility of the economic
results
No
Pegaptanib Wet age-related
macular
degeneration
Restricted by
SMC, not
recommended
by NICE
SMC: approved for restricted use in July 2006
NICE: deemed not cost-effective in August
2008 in an MTA along with ranibizumab,
which was considered cost-effective
N.B SMC have changed their advice in
accordance with NICE MTA
No
Sunitinib
(ﬁrst line)
Advanced and/or
metastatic renal
cell carcinoma
Recommended
by NICE, but not
by SMC
SMC (July 2007): manufacturer did not
present a sufﬁciently robust economic analysis
NICE (March 2009): approved for restricted
use in one subgroup, with ﬁrst cycle free to
NHS, and cost per QALY of £54000 under
the ‘end-of-life’ system
N.B SMC have changed their advice in
accordance with NICE MTA
Yes
Trabectedin
Intravenous
Advanced soft
tissue sarcoma
Recommended
by NICE, but not
by SMC
SMC: manufacturer did not present a
sufﬁciently robust economic analysis
NICE: restricted use with ICER at £34000,
with a ‘patient access scheme’, in which
manufacturer funds the sixth and any
further treatments. Approved under
end-of-life system
Yes
Adalimumab Severe active
Crohn’s disease
(adults)
Recommended
by NICE, but
not by SMC
SMC (October 2007): manufacturer did
not present a sufﬁciently robust economic
case
NICE (May 2010): restricted use. NICE
did not agree with the assessment group
assumptions about relapse rates and
obtained further analyses from its Decision
Support Unit. The ﬁnal NICE cost per QALY
estimate is not clear
No
Continued
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NICE, the STA process and SMCcontrast, NICE serves a population >10 times the size,
and it would not be possible for every Primary Care Trust
or trust to be represented on the appraisal committees.
The wide consultation by NICE may reduce the risk of
legal challenge. NICE is probably more likely to be
challenged than SMC for two reasons. First, NICE guid-
ance is used more as a reference for pricing negotiations
by other countries. Second, NICE guidance is ﬁxed for
(usually) 3 years, whereas a manufacturer whose medi-
cine has not been recommended can re-submit to SMC
at any time.
Consultation by NICE starts well before the actual
appraisal, with scoping meetings, and even a consulta-
tion on who should be consulted. After the scoping
process, NICE makes a recommendation to the DH as to
whether a drug should be appraised. The DH then
decides on whether or not to formally refer the drug to
NICE. This process takes about 3 months (from scoping
meeting to formal referral). However, this consultation
and referral process usually happens before marketing
authorisation and so is unlikely to be relevant to the
timelines examined in this paper. Sir Michael Rawlins,
chair of NICE, has suggested that for NICE to produce
guidance within 6 months of marketing authorisation, it
needs to begin the appraisal process about 15 months
before anticipated launch.
8 In contrast, SMC just looks at
all new drugs, so no selection process is needed. This
also has the advantage of complete clarity for industry
since they know that if they are taking a medicine
through the European licensing process, then (when
successful) they will deﬁnitely be expected to provide
a submission by SMC so they can plan for this at an early
stage, whereas at that stage, they may not know whether
it will be referred to NICE.
Reasons for lengthier appraisal for cancer drugs
One possible explanation for longer timelines for cancer
drugs is that many are expensive and hence costs per
QALY may be more likely to be on the border of
affordability. Another possibility may be that the
evidence base for new cancer drugs is limited at the time
of appraisal, so the cost per QALY may be more uncer-
tain. This represents a challenge to the appraisal
committee, for example, trying to identify subgroups
and stopping/starting rules. Additional analysis may be
sought from the Evidence Review Group or the manu-
facturer. All this generates delay.
Strengths and weaknesses
We included only drugs assessed through the technology
appraisal programme at NICE and will have missed a few
appraised through the guideline process.
9 Appraisal
outcomes were collected from published tables on the
NICE website or SMC annual reports.
One problem is the deﬁnition of restricted. We have
mentioned above the pimecrolimus example, which is
Table 3 Continued
NICE product Condition Decisions Reason PAS
Efaluzimab Psoriasis Restricted use
approved by
NICE, not
recommended
by SMC
SMC: cost-effectiveness was not
demonstrated
NICE: Maybe a treatment option if disease
is severe as deﬁned by a total Psoriasis
Area Severity Index (PASI) of 10 or more
and a Dermatology Life Quality Index
(DLQI) of >10. The psoriasis has failed
to respond to standard systemic therapies
including ciclosporin, methotrexate and PUVA;
or the person is intolerant to, or has a
contraindication to, these treatments and
only if their psoriasis has failed to respond to
etanercept or they are shown to be intolerant
of, or have contraindications to, treatment with
etanercept
N.B The license has been withdrawn from
EMA due to a possible link with multifocal
leukoencephalopathy
No
EMA, European Medicines Agency; ICER, incremental cost-effectiveness ratio; MTA, multiple technology assessments; NICE, National
Institute of Health and Clinical Excellence; PAS, Patient Access Scheme; PUVA, Psoralen and Ultraviolet Light A; SMC, Scottish Medicines
Consortium.
Table 4 NICE and SMC ﬁnal outcome
Final outcome NICE SMC
Recommended, No.
of drugs (%)
173 (71.5) 218 (39.3)
Restricted, No. of
drugs (%)
45 (18.6) 228 (41.1)
Not recommended, No.
of drugs (%)
24 (9.9) 109 (19.6)
NICE, National Institute of Health and Clinical Excellence; SMC,
Scottish Medicines Consortium.
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NICE, the STA process and SMCdeﬁned as ‘recommended’ by NICE but for very
restricted use. Many drugs are recommended by NICE
and SMC for use in specialist care only, but this would
probably not be regarded as ‘restricted use’ by most
people. On other occasions, NICE has approved drugs
for narrower use than the licensed indications. For
example, liraglutide and exenatide are licensed for use
in dual therapy, but NICE has recommended them for
use only in triple therapy, albeit with a very few excep-
tions in dual therapy. Other examples include restriction
on the grounds of prior treatment, ﬁtness states and
blood glucose levels.
If we adopted a broader deﬁnition of restricted, then
one could argue that the majority of NICE approvals are
for restricted use.
How does this compare to other studies
Only a few studies have looked at the differences
between NICE, SMC and the impact of the new STA
system.
7 10 11 In 2007, Dear et al found a different
outcome in ﬁve out of 35 comparable decisions (14.3%),
with an average of 12 months difference between SMC
and NICE.
8 In 2008, Barham
11 reported that the interval
between marketing authorisation and guidance publi-
cation was longer for cancer STAs than MTAs.
Dear et al also compared time differences between
SMC and NICE in 2007.
10 Based on 35 drugs, they esti-
mated the time difference between SMC and NICE to be
12 months. Our results show the difference to be closer
to 17 months based on 88 comparable medications;
however, when looking at only STAs, this was approxi-
mately 12 months. Dear et al also found an acceptance
rate of 64% by SMC, although this does not take into
account re-submissions. Our data show an acceptance
rate of about 80%, which probably reﬂects our use of
only ﬁnal SMC decisions, some after re-submissions.
Barbieri and colleagues (2009) reviewed decisions on
25 cases where NICE and SMC guidances could be
compared and found general agreement in terms of
recommendations for use in 23 cases.
7 However, they
noted that NICE was sometimes more restrictive than
SMC, for example, recommending that use be limited to
subgroups based on age or failure of previous treatment.
They give an example, alendronate for osteoporosis,
approved without restriction by SMC but restricted to
age and risk status subgroups by NICE. In this case, the
appraisal was done under the previous NICE MTA
process involving an independent assessment report by
an academic group. Barbieri and colleagues also noted
that the interval between SMC and NICE appraisals
could be as long as 2 years, which could lead to different
decisions because of an increasing evidence base.
Mason and colleagues (2010)
12 reported that for the
period 2004e2008, the STA process had not shortened
the timelines compared to MTAs, for cancer drugs, but
did not examine non-cancer medications. They also
examined time to coverage in the USA and noted that
within cancer therapy, hormonal drugs became available
faster than chemotherapy drugs, which were in turn
faster than biological agents. However, timelines varied
among US providers such as Veterans Affairs and
Regence.
Barbieri and colleagues (2009) also reviewed the role
of independent third party assessment and concluded
that it had advantages but that it tended to take longer,
as found in this study for non-cancer drugs.
7 However,
they argued that the third party system, as was provided
to NICE by the academic groups, need not prolong the
timelines. Indeed, they suggested that basing the
appraisal on manufacturers’ submissions might lead to
delays if there had to be an iterative process of
requesting further data or analyses.
How many bodies does the UK need to evaluate new drugs?
In addition to NICE and SMC, there are systems in Wales
and Northern Ireland. The All Wales Medicines Strategy
Group evaluates new medicines for the NHS in Wales.
However, it aims to avoid duplication with NICE, though
it may produce interim advice pending a NICE appraisal,
and only assesses up to 32 new medicines a year.
In Northern Ireland, there has been since 2006
a system whereby NICE guidance is assessed for suit-
ability for implementation in the Province, with the
expectation that is normally will be adopted.
13 There is
also a Regional Group on Specialist Medicines, which
can issue advice on drugs not appraised by NICE.
The existence of the several bodies making policy on
new drugs reﬂects the impact of devolution and separate
development of the NHS in the four territories of the
UK.
Licensing is now carried out on a Europedwide basis
but that is more of a technical judgement of efﬁcacy and
safety. Health technology assessment of new medicines
takes into account a wider range of factors such as will-
ingness and ability to pay for the beneﬁts accrued locally,
deﬁnition of value, accountability to local parliaments,
local clinician buy-in and clinical guidelines.
Conclusions
The introduction of the NICE STA system has been
associated with reduced time to publication of guidance
for non-cancer drugs, but for cancer drugs, the STA
timelines are little different from MTA timelines.
Signiﬁcant differences remain in timescales between
SMC and NICE. There are also some differences in
guidances between the organisations, but the differences
in terms of approved/not approved are often minor,
such as approved for very restricted use/not approved.
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